A DURABLE phase II trial is reported to have found that maintenance treatment with durvalumab plus anlotinib outperformed durvalumab alone in extensive-stage small-cell lung cancer, according to the provided overview of upcoming ASCO-related data. The study evaluated efficacy and biomarker profiles tied to the dual maintenance strategy. If the findings are sustained through full presentation, the regimen could offer a new maintenance pathway in a high-need segment where maintenance options have historically been limited and response durability can be modest. The report frames the update as a pivotal evidence point ahead of expanded analyses and poster-orals at major oncology congresses.